Get notified when CPHI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Offering Price of $2.00 Per Share, Significantly Below the Recent Closing Price of $8.10 (new) — The steep discount to market suggests the company may be in urgent need of capital or facing difficulty attracting investors at higher valuations.
- Immediate Dilution of $1.98 Per Share to New Investors (new) — New investors pay $2.00 for shares with a pro forma net tangible book value of only $0.02, representing a 99% immediate loss in book value.
- We Have Not Allocated Specific Amounts of the Net Proceeds From This Offering For Any Specific Purpose (new) — Management has broad discretion over the use of proceeds, making it difficult for investors to assess how the funds will be deployed.
China Pharma Holdings prices $5M primary offering at $2.00/share, a 75% discount to last close
Filed July 23, 2026 · ~1 min read
Key Changes
-
high
China Pharma Holdings is selling 2,500,000 primary shares at $2.00 each, raising $5.0M gross and $4.4M net for the company.
The Offering verify on EDGAR → -
high
The $2.00 offer price is 75% below the $8.10 closing price on July 21, 2026, signaling potential urgency for capital.
The Offering verify on EDGAR → -
medium
Net proceeds of $4.4M are earmarked for working capital and general corporate purposes, with management retaining broad discretion.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.
Partner
Trade CPHI commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify